Immediate vs. Points-Based Rewards
Points based programs delay reinforcement of positive behavior, weakening the association between action and reward. Each day of delay between the behavior and the reward reduces the reward’s perceived value by about 5%; after a two-week delay, the impact of a reward is roughly halved.
Making Remote Work Really Work
Remote work is no longer just a pandemic necessity, it is firmly established in the workplace. And remote workers are more engaged than their office-bound counterparts.
Unused. Unclaimed. Unfair.
Incentive rewards companies are costing you serious money while promising you “free” delivery. The right Incentive Automation platform eliminates the confusion.
Emerging Trends in Research Payments
In the world of research payments—whether academic, clinical, or market-based—participant engagement is critical to success.
The Perfect Survey Participation Thank You Email
The U.S. Food and Drug Administration (FDA) and the American Medical Association (AMA) took significant steps in 2024 to address disparities in clinical research participation.
Sales Incentives
Short-term sales incentives boost performance and motivate sales staff to go the extra mile and improve sales success.
The Real Economics of Gift Cards
Gift cards are a key component of the incentive, payments, and rewards industry, but their financial intricacies and economics are often misunderstood.
Retention and Engagement Starts Here
Engaging and retaining employees is essential for the success of any organization. Keeping top talent and qualified employees onboard comes with big perks, like reducing the endless cycle of recruiting, onboarding and training new hires.
Small Acts, Big Impact
Gratitude and appreciation are powerful tools that positively influence employee well-being and enhance the success of your organization.
Employees that feel appreciated report being more engaged and motivated, which adds to productivity and an increase in job satisfaction.
Upholding Equity in Clinical Research
The U.S. Food and Drug Administration (FDA) and the American Medical Association (AMA) took significant steps in 2024 to address disparities in clinical research participation.